Top 5 Drug Type | Count |
---|---|
Small molecule drug | 16 |
Antibody drug conjugate (ADC) | 5 |
Monoclonal antibody | 3 |
Chemical drugs | 1 |
Fusion protein | 1 |
Target |
Mechanism CXCR4 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date26 Apr 2024 |
Target |
Mechanism CALCRL antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date27 Feb 2020 |
Target |
Mechanism XPO1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date03 Jul 2019 |
Start Date01 May 2024 |
Sponsor / Collaborator ![]() [+2] |
Start Date13 Mar 2024 |
Sponsor / Collaborator |
Start Date11 Mar 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Tamoxifen Citrate ( ER ) | Noninfiltrating Intraductal Carcinoma More | Approved |
Calcipotriene ( VDR ) | Plaque psoriasis More | Approved |
Lanadelumab ( Kallikreins ) | Hereditary Angioedema More | Approved |
Nicotinamide | Pellagra More | Approved |
Durvalumab ( PDL1 ) | - | NDA/BLA |